Growth, tolerance, and DHA and ARA status of healthy term infants receiving formula with two different ARA concentrations: Double-blind, randomized, controlled trial

In this study, healthy term infants received study formula through 120 days of age. All study formulas had 17 mg DHA/100 kcal. Investigational formulas had 1) ARA at 25/mg 100 kcal and no added prebiotic blend (ARA-25; n=29) or 2) 34 mg ARA 100/kcal and a prebiotic blend (1:1 ratio; 4g/L) of polydextrose and galactooligosaccharides (PDX/GOS; n=20). The control formula had 34 mg ARA/100 kcal and no added prebiotic blend (Control: n=31). Fatty acids in total RBCs and plasma phospholipids (PPLs) at 120 days and buccal epithelial PLs at 14 and 120 days of age were assessed by capillary column gas chromatography. The calculated 90% confidence interval (CI) of each investigational formula relative to the Control for total RBC ARA (ARA-25: 93-105%; PDX/GOS: 96-110%) and total RBC DHA (ARA-25: 95-113%; PDX/GOS: 94-113%) fell within the pre-specified equivalence limit (85–118%), establishing study formula equivalence with respect to ARA and DHA. At day 120, total RBC and buccal epithelia PL ARA (μg/ml) were not significantly correlated (r=0.041; p=0.732); correlation in total RBC and buccal epithelia PL DHA was low, albeit significant (r=0.324; p=0.006). Consequently, buccal epithelial may not provide a suitable substitute for RBC when assessing fatty acid status and availability. The present RBC data suggest availability of DHA for central nervous system development and function is equivalent among infants receiving formulas that had 34 or 25 mg/100 kcal ARA and 17 mg/100 kcal DHA...

Source: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) - May 1, 2019 Category: Lipidology Source Type: research